Clinical Trial Update: Avastin and Temsirolimus Following Tyrosine Kinase Inhibitor Failure in Patients With Advanced Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Avastin and Temsirolimus after tyrosine kinase inhibitor failure in advanced renal cell carcinoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Avastin (bevacizumab)
• Temsirolimus (temsirolimus)

Snippet

Sponsor: Beth Israel Deaconess Medical Center | Conditions: Renal Cell Carcinoma, Kidney Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-12-20